The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement: Explanation and Elaboration
暂无分享,去创建一个
Sally Morton | John Ioannidis | Ewout Steyerberg | Ravi Varadhan | Gowri Raman | David van Klaveren | Ralph D'Agostino | Michael Pencina | David Kent | Bray Patrick-Lake | R. Varadhan | J. Ioannidis | M. Pencina | R. D'Agostino | D. van Klaveren | E. Steyerberg | J. Paulus | D. Kent | A. Vickers | S. Morton | G. Raman | R. Hayward | H. Selker | S. Goodman | B. Patrick-Lake | Joseph Ross | John B. Wong | Jessica Paulus | Steve Goodman | Rodney Hayward | Joseph Ross | Harry Selker | Andrew Vickers | John Wong
[1] Sally Morton,et al. The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement , 2019, Annals of Internal Medicine.
[2] Ewout W Steyerberg,et al. Models with interactions overestimated heterogeneity of treatment effects and were prone to treatment mistargeting. , 2019, Journal of clinical epidemiology.
[3] G. Molenberghs,et al. Aligning Estimators With Estimands in Clinical Trials: Putting the ICH E9(R1) Guidelines Into Practice. , 2019, Therapeutic innovation & regulatory science.
[4] G. Molenberghs,et al. Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into Practice. , 2019, Therapeutic innovation & regulatory science.
[5] D. van Klaveren,et al. Risk stratification of sentinel node positive melanoma patients defines surgical management and adjuvant therapy treatment considerations , 2019, European Journal of Surgical Oncology.
[6] L. Hazell,et al. Analysis and reporting of adverse events in randomised controlled trials: a review , 2019, BMJ Open.
[7] Benjamin Djulbegovic,et al. Precision medicine for individual patients should use population group averages and larger, not smaller, groups , 2019, European journal of clinical investigation.
[8] Tyler J. VanderWeele,et al. Selecting Optimal Subgroups for Treatment Using Many Covariates , 2018, Epidemiology.
[9] S. Schandelmaier. EVALUATING THE CREDIBILITY OF EFFECT MODIFICATION CLAIMS IN RANDOMIZED CONTROLLED TRIALS AND META-ANALYSES , 2019 .
[10] K. Furie,et al. Scoring System to Optimize Pioglitazone Therapy After Stroke Based on Fracture Risk , 2019, Stroke.
[11] Ewout Steyerberg,et al. Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects , 2018, British Medical Journal.
[12] J. Ioannidis,et al. How often can meta-analyses of individual-level data individualize treatment? A meta-epidemiologic study. , 2018, International journal of epidemiology.
[13] Amit J. Shah,et al. Use of High-Sensitivity Cardiac Troponin for the Exclusion of Inducible Myocardial Ischemia , 2018, Annals of Internal Medicine.
[14] Catherine R. Lesko,et al. Considerations when assessing heterogeneity of treatment effect in patient-centered outcomes research. , 2018, Journal of clinical epidemiology.
[15] Ewout W. Steyerberg,et al. Big Data and Predictive Analytics: Recalibrating Expectations , 2018, JAMA.
[16] R. Kravitz,et al. Evaluation of person-level heterogeneity of treatment effects in published multiperson N-of-1 studies: systematic review and reanalysis , 2018, BMJ Open.
[17] D. Scharfstein,et al. Cautions as Regulators Move to End Exclusive Reliance on Intention to Treat , 2018, Annals of Internal Medicine.
[18] Ewout W Steyerberg,et al. The proposed 'concordance-statistic for benefit' provided a useful metric when modeling heterogeneous treatment effects. , 2018, Journal of clinical epidemiology.
[19] Matthew M. Chingos,et al. The Review of Economics and Statistics , 2018 .
[20] K. Furie,et al. Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial Infarction , 2017, JAMA neurology.
[21] P. Noseworthy,et al. Comparison of the CHA2DS2-VASc, CHADS2, HAS-BLED, ORBIT, and ATRIA Risk Scores in Predicting Non-Vitamin K Antagonist Oral Anticoagulants-Associated Bleeding in Patients With Atrial Fibrillation. , 2017, The American journal of cardiology.
[22] James M Robins,et al. Per-Protocol Analyses of Pragmatic Trials. , 2017, The New England journal of medicine.
[23] Sanjay Basu,et al. Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials , 2017, PLoS medicine.
[24] Sebastian Schneeweiss,et al. When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials? , 2017, Clinical pharmacology and therapeutics.
[25] Jennifer L Krull,et al. Advancing Personalized Medicine: Application of a Novel Statistical Method to Identify Treatment Moderators in the Coordinated Anxiety Learning and Management Study. , 2017, Behavior therapy.
[26] Kristin L. Sainani,et al. Evaluation of Evidence of Statistical Support and Corroboration of Subgroup Claims in Randomized Clinical Trials , 2017, JAMA internal medicine.
[27] Deepak L. Bhatt,et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials , 2017, The Lancet.
[28] Gowri Raman,et al. Tufts PACE Clinical Predictive Model Registry: update 1990 through 2015 , 2017, Diagnostic and Prognostic Research.
[29] F. Davidoff. Can Knowledge About Heterogeneity in Treatment Effects Help Us Choose Wisely? , 2017, Annals of Internal Medicine.
[30] I. Lipkovich,et al. Tutorial in biostatistics: data‐driven subgroup identification and analysis in clinical trials , 2017, Statistics in medicine.
[31] Federico Rotolo,et al. Identification of biomarker‐by‐treatment interactions in randomized clinical trials with survival outcomes and high‐dimensional spaces , 2016, Biometrical journal. Biometrische Zeitschrift.
[32] Eva Petkova,et al. Generated effect modifiers (GEM's) in randomized clinical trials. , 2017, Biostatistics.
[33] Zachary F. Meisel,et al. Shared decision making in patients with low risk chest pain: prospective randomized pragmatic trial , 2016, British Medical Journal.
[34] Issa J Dahabreh,et al. Risk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trials. , 2016, International journal of epidemiology.
[35] Issa J Dahabreh,et al. Using group data to treat individuals: understanding heterogeneous treatment effects in the age of precision medicine and patient-centred evidence. , 2016, International journal of epidemiology.
[36] J. Ioannidis,et al. Sex based subgroup differences in randomized controlled trials: empirical evidence from Cochrane meta-analyses , 2016, British Medical Journal.
[37] Mithat Gönen,et al. A new concordance measure for risk prediction models in external validation settings , 2016, Statistics in medicine.
[38] Richard D Riley,et al. Explicit inclusion of treatment in prognostic modeling was recommended in observational and randomized settings. , 2016, Journal of clinical epidemiology.
[39] Heenam Seo,et al. Trends in endpoint selection in clinical trials of advanced breast cancer , 2016, Journal of Cancer Research and Clinical Oncology.
[40] J. Spertus,et al. Understanding physician-level barriers to the use of individualized risk estimates in percutaneous coronary intervention. , 2016, American heart journal.
[41] Philip W Lavori,et al. Integrating Randomized Comparative Effectiveness Research with Patient Care. , 2016, The New England journal of medicine.
[42] J. Spertus,et al. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. , 2016, JAMA.
[43] James E. Helmreich. Regression Modeling Strategies with Applications to Linear Models, Logistic and Ordinal Regression and Survival Analysis (2nd Edition) , 2016 .
[44] Ewout W Steyerberg,et al. Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests , 2016, British Medical Journal.
[45] L. Eckardt,et al. Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms , 2016, Nature Reviews Cardiology.
[46] James F Burke,et al. Three simple rules to ensure reasonably credible subgroup analyses , 2015, BMJ : British Medical Journal.
[47] Yvonne Vergouwe,et al. Estimates of absolute treatment benefit for individual patients required careful modeling of statistical interactions. , 2015, Journal of clinical epidemiology.
[48] James F Burke,et al. Implications of Heterogeneity of Treatment Effect for Reporting and Analysis of Randomized Trials in Critical Care. , 2015, American journal of respiratory and critical care medicine.
[49] Menggang Yu,et al. Regularized outcome weighted subgroup identification for differential treatment effects , 2015, Biometrics.
[50] Daniel J Sargent,et al. The Fundamental Difficulty With Evaluating the Accuracy of Biomarkers for Guiding Treatment. , 2015, Journal of the National Cancer Institute.
[51] Richard Simon,et al. Sensitivity, Specificity, PPV, and NPV for Predictive Biomarkers. , 2015, Journal of the National Cancer Institute.
[52] Jason P Fine,et al. On the quantitative assessment of predictive biomarkers. , 2015, Journal of the National Cancer Institute.
[53] J. Afilalo,et al. Outcome Reporting in Cardiac Surgery Trials: Systematic Review and Critical Appraisal , 2015, Journal of the American Heart Association.
[54] Michael I. Jordan,et al. Machine learning: Trends, perspectives, and prospects , 2015, Science.
[55] J. Spertus,et al. Realizing the Potential of Clinical Risk Prediction Models: Where Are We Now and What Needs to Change to Better Personalize Delivery of Care? , 2015, Circulation. Cardiovascular quality and outcomes.
[56] B. Wessler,et al. Clinical Prediction Models for Cardiovascular Disease: Tufts Predictive Analytics and Comparative Effectiveness Clinical Prediction Model Database , 2015, Circulation. Cardiovascular quality and outcomes.
[57] D. Kent,et al. The Lake Wobegon Effect: Why Most Patients Are at Below-Average Risk , 2015, Annals of Internal Medicine.
[58] H. Weisberg,et al. Post hoc subgroups in clinical trials: Anathema or analytics? , 2015, Clinical trials.
[59] Geoffrey E. Hinton,et al. Deep Learning , 2015, Nature.
[60] Richard D Riley,et al. Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data: The PRISMA-IPD Statement , 2015 .
[61] Niko Kaciroti,et al. Simple subgroup approximations to optimal treatment regimes from randomized clinical trial data. , 2015, Biostatistics.
[62] Wenting Cheng,et al. Reader reaction to “A robust method for estimating optimal treatment regimes” by Zhang et al. (2012) , 2015, Biometrics.
[63] Jeremy B Sussman,et al. Improving diabetes prevention with benefit based tailored treatment: risk based reanalysis of Diabetes Prevention Program , 2015, BMJ : British Medical Journal.
[64] Gary S Collins,et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration , 2015, Annals of Internal Medicine.
[65] G. Collins,et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): The TRIPOD Statement , 2015, Annals of Internal Medicine.
[66] A. Philip Dawid,et al. On individual risk , 2014, Synthese.
[67] Ich Harmonised,et al. INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED GUIDELINE GENERAL CONSIDERATIONS FOR CLINICAL STUDIES E8(R1) , 2019 .
[68] Lee-Jen Wei,et al. Treatment selections using risk-benefit profiles based on data from comparative randomized clinical trials with multiple endpoints. , 2015, Biostatistics.
[69] Tyler J. VanderWeele,et al. A Tutorial on Interaction , 2014 .
[70] Zhiwei Zhang,et al. The Use of Covariates and Random Effects in Evaluating Predictive Biomarkers Under a Potential Outcome Framework. , 2014, The annals of applied statistics.
[71] P. Sandercock,et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials | NOVA. The University of Newcastle's Digital Repository , 2014 .
[72] Issa J Dahabreh,et al. Can the learning health care system be educated with observational data? , 2014, JAMA.
[73] Jennifer G. Robinson,et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.
[74] L. Smeeth,et al. Use of electronic healthcare records in large‐scale simple randomized trials at the point of care for the documentation of value‐based medicine , 2014, Journal of internal medicine.
[75] Thomas Agoritsas,et al. How to use a subgroup analysis: users' guide to the medical literature. , 2014, JAMA.
[76] Richard D Riley,et al. Developing and validating risk prediction models in an individual participant data meta-analysis , 2014, BMC Medical Research Methodology.
[77] J. Berger,et al. A Bayesian Approach to Subgroup Identification , 2014, Journal of biopharmaceutical statistics.
[78] David M. Kent,et al. Using Internally Developed Risk Models to Assess Heterogeneity in Treatment Effects in Clinical Trials , 2014, Circulation. Cardiovascular quality and outcomes.
[79] Lu Tian,et al. A Simple Method for Detecting Interactions between a Treatment and a Large Number of Covariates , 2012, 1212.2995.
[80] Yu-Ming Shen. Assessing Treatment-Selection Markers using a Potential Outcomes Framework , 2014 .
[81] Stephanie Kovalchik,et al. Assessing heterogeneity of treatment effect in a clinical trial with the proportional interactions model , 2013, Statistics in medicine.
[82] Ellen Frank,et al. A novel approach for developing and interpreting treatment moderator profiles in randomized clinical trials. , 2013, JAMA psychiatry.
[83] James M Robins,et al. Randomized Trials Analyzed as Observational Studies , 2013, Annals of Internal Medicine.
[84] Karel G M Moons,et al. A framework for developing, implementing, and evaluating clinical prediction models in an individual participant data meta‐analysis , 2013, Statistics in medicine.
[85] Ravi Varadhan,et al. A framework for the analysis of heterogeneity of treatment effect in patient-centered outcomes research. , 2013, Journal of clinical epidemiology.
[86] Harlan M. Krumholz,et al. A Historic Moment for Open Science: The Yale University Open Data Access Project and Medtronic , 2013, Annals of Internal Medicine.
[87] S. Ghimire,et al. Reporting Trends of Outcome Measures in Phase II and Phase III Trials Conducted in Advanced-Stage Non-small-cell Lung Cancer , 2013, Lung.
[88] Helena Chmura Kraemer,et al. Discovering, comparing, and combining moderators of treatment on outcome after randomized clinical trials: a parametric approach , 2013, Statistics in medicine.
[89] Antonio Colombo,et al. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II , 2013, The Lancet.
[90] Richard D Riley,et al. Prognosis research strategy (PROGRESS) 4: Stratified medicine research , 2013, BMJ : British Medical Journal.
[91] Richard D Riley,et al. Prognosis research strategy (PROGRESS) 1: A framework for researching clinical outcomes , 2013, BMJ : British Medical Journal.
[92] Lu Tian,et al. Effectively Selecting a Target Population for a Future Comparative Study , 2013, Journal of the American Statistical Association.
[93] E. Steyerberg,et al. Prognosis Research Strategy (PROGRESS) 2: Prognostic Factor Research , 2013, PLoS medicine.
[94] E. Steyerberg,et al. Prognosis Research Strategy (PROGRESS) 3: Prognostic Model Research , 2013, PLoS medicine.
[95] R. Herings,et al. Risk of Fracture with Thiazolidinediones: An Individual Patient Data Meta-Analysis , 2012, Front. Endocrinol..
[96] Eric B. Laber,et al. A Robust Method for Estimating Optimal Treatment Regimes , 2012, Biometrics.
[97] R. Little,et al. The prevention and treatment of missing data in clinical trials. , 2012, The New England journal of medicine.
[98] Stuart G Baker,et al. Evaluating a new marker for risk prediction: decision analysis to the rescue. , 2012, Discovery medicine.
[99] D. Kent,et al. Risk models and patient-centered evidence: should physicians expect one right answer? , 2012, JAMA.
[100] A. Vickers,et al. Against quantiles: categorization of continuous variables in epidemiologic research, and its discontents , 2012, BMC Medical Research Methodology.
[101] Min Zhang,et al. Estimating optimal treatment regimes from a classification perspective , 2012, Stat.
[102] Ewout W Steyerberg,et al. Estimating treatment effects for individual patients based on the results of randomised clinical trials , 2011, BMJ : British Medical Journal.
[103] John P. A. Ioannidis,et al. Individualized Cost-Effectiveness Analysis , 2011, PLoS medicine.
[104] T. VanderWeele,et al. Interpretation of Subgroup Analyses in Randomized Trials: Heterogeneity Versus Secondary Interventions , 2011, Annals of Internal Medicine.
[105] L. Tian,et al. Analysis of randomized comparative clinical trial data for personalized treatment selections. , 2011, Biostatistics.
[106] S. Murphy,et al. PERFORMANCE GUARANTEES FOR INDIVIDUALIZED TREATMENT RULES. , 2011, Annals of statistics.
[107] S. Murphy,et al. Variable Selection for Qualitative Interactions. , 2011, Statistical methodology.
[108] David M Kent,et al. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal , 2010, Trials.
[109] Jeremy B Sussman,et al. An IV for the RCT: using instrumental variables to adjust for treatment contamination in randomised controlled trials , 2010, BMJ : British Medical Journal.
[110] R. Riley,et al. Meta-analysis of individual participant data: rationale, conduct, and reporting , 2010, BMJ : British Medical Journal.
[111] Gregory Y H Lip,et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.
[112] Debashis Ghosh,et al. Bayesian Variable Selection with Joint Modeling of Categorical and Survival Outcomes: An Application to Individualizing Chemotherapy Treatment in Advanced Colorectal Cancer , 2009, Biometrics.
[113] S. Baker. Putting risk prediction in perspective: relative utility curves. , 2009, Journal of the National Cancer Institute.
[114] Mohamed Alfateh Badawy,et al. Identification of children at very low risk of clinically-important brain injuries after head trauma: a prospective cohort study , 2009, The Lancet.
[115] G. Bedogni,et al. Clinical Prediction Models—a Practical Approach to Development, Validation and Updating , 2009 .
[116] Nancy R Cook,et al. Using relative utility curves to evaluate risk prediction , 2009, Journal of the Royal Statistical Society. Series A,.
[117] M. Hanefeld,et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial , 2009, The Lancet.
[118] P. Scardino,et al. The clinically-integrated randomized trial: proposed novel method for conducting large trials at low cost , 2009, Trials.
[119] C. Furberg,et al. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis , 2009, Canadian Medical Association Journal.
[120] J. Ioannidis. Why Most Discovered True Associations Are Inflated , 2008, Epidemiology.
[121] S. Pocock,et al. More on subgroup analyses in clinical trials. , 2008, The New England journal of medicine.
[122] Patrick Royston,et al. Multivariable Model-Building: A Pragmatic Approach to Regression Analysis based on Fractional Polynomials for Modelling Continuous Variables , 2008 .
[123] James A Hanley,et al. Profile-specific survival estimates: Making reports of clinical trials more patient-relevant , 2008, Clinical trials.
[124] Douglas G. Altman,et al. Effect Measures for Meta‒Analysis of Trials with Binary Outcomes , 2008 .
[125] James M. Robins,et al. Empirical and counterfactual conditions for sufficient cause interactions , 2008 .
[126] Yingye Zheng,et al. Integrating the predictiveness of a marker with its performance as a classifier. , 2007, American journal of epidemiology.
[127] R. Garrick. Progression Risk, Urinary Protein Excretion, and Treatment Effects of Angiotensin-Converting Enzyme Inhibitors in Nondiabetic Kidney Disease , 2008 .
[128] Stephen W Lagakos,et al. Statistics in medicine--reporting of subgroup analyses in clinical trials. , 2007, The New England journal of medicine.
[129] David M Kent,et al. Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. , 2007, JAMA.
[130] J. Robins,et al. Four Types of Effect Modification: A Classification Based on Directed Acyclic Graphs , 2007, Epidemiology.
[131] Andrew J Vickers,et al. Method for evaluating prediction models that apply the results of randomized trials to individual patients , 2007, Trials.
[132] Ralph B D'Agostino,et al. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. , 2007, Archives of internal medicine.
[133] James M Robins,et al. The Identification of Synergism in the Sufficient-Component-Cause Framework , 2007, Epidemiology.
[134] J. Pogue,et al. Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. , 2007, European heart journal.
[135] I. White,et al. Instrumental variables and interactions in the causal analysis of a complex clinical trial , 2007, Statistics in medicine.
[136] S Claiborne Johnston,et al. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack , 2007, The Lancet.
[137] D. Jacobs,et al. Comparison of body mass index, waist circumference, and waist/hip ratio in predicting incident diabetes: a meta-analysis. , 2007, Epidemiologic reviews.
[138] E. Elkin,et al. Decision Curve Analysis: A Novel Method for Evaluating Prediction Models , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.
[139] S. Lagakos. The challenge of subgroup analyses--reporting without distorting. , 2006, The New England journal of medicine.
[140] David M Kent,et al. Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis , 2006, BMC medical research methodology.
[141] J. Habbema,et al. Subgroup analyses in therapeutic cardiovascular clinical trials: are most of them misleading? , 2006, American heart journal.
[142] D. Kent,et al. Reporting clinical trial results to inform providers, payers, and consumers. , 2005, Health affairs.
[143] L. Køber,et al. Simple Risk Stratification at Admission to Identify Patients With Reduced Mortality From Primary Angioplasty , 2005, Circulation.
[144] P. Poole‐Wilson,et al. 5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial , 2005, The Lancet.
[145] S. Gutnikov,et al. From subgroups to individuals: general principles and the example of carotid endarterectomy , 2005, The Lancet.
[146] P. Rothwell. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation , 2005, The Lancet.
[147] Tomas Andersson,et al. Calculating measures of biological interaction , 2005, European Journal of Epidemiology.
[148] A. Ahlbom,et al. Interaction: A word with two meanings creates confusion , 2005, European Journal of Epidemiology.
[149] Richard L Kravitz,et al. Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. , 2004, The Milbank quarterly.
[150] S. Senn. Individual response to treatment: is it a valid assumption? , 2004, BMJ : British Medical Journal.
[151] B. Gage,et al. Selecting Patients With Atrial Fibrillation for Anticoagulation: Stroke Risk Stratification in Patients Taking Aspirin , 2004, Circulation.
[152] D. Kent,et al. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction. , 2004, Journal of clinical epidemiology.
[153] Scott Hamilton,et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials , 2004, The Lancet.
[154] Sara T Brookes,et al. Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test. , 2004, Journal of clinical epidemiology.
[155] Brian H Rowe,et al. The Canadian C-spine rule versus the NEXUS low-risk criteria in patients with trauma. , 2003, The New England journal of medicine.
[156] Sunil J Rao,et al. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2003 .
[157] D. Kent,et al. Are Some Patients Likely to Benefit From Recombinant Tissue-Type Plasminogen Activator for Acute Ischemic Stroke Even Beyond 3 Hours From Symptom Onset? , 2003, Stroke.
[158] Harry P. Selker,et al. Use of the electrocardiograph-based thrombolytic predictive instrument to assist thrombolytic and reperfusion therapy for acute myocardial infarction: a multicenter, randomized, controlled, clinical effectiveness trial☆ , 2002 .
[159] S. Pocock,et al. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practiceand problems , 2002, Statistics in medicine.
[160] R. Califf,et al. An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase. , 2002, The American journal of medicine.
[161] J. Griffith,et al. Use of the Electrocardiograph-Based Thrombolytic Predictive Instrument To Assist Thrombolytic and Reperfusion Therapy for Acute Myocardial Infarction: A Multicenter, Randomized, Controlled, Clinical Effectiveness Trial , 2002, Annals of Internal Medicine.
[162] S. Fowler,et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .
[163] J. Sterne,et al. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. , 2001, Journal of clinical epidemiology.
[164] C. Schmid,et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. , 2001, Kidney international.
[165] G. Kovacs,et al. Excluding Pulmonary Embolism at the Bedside without Diagnostic Imaging: Management of Patients with Suspected Pulmonary Embolism Presenting to the Emergency Department by Using a Simple Clinical Model and d-dimer , 2001, Annals of Internal Medicine.
[166] Martha J. Radford,et al. Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .
[167] J. Ioannidis,et al. Predictive modeling and heterogeneity of baseline risk in meta-analysis of individual patient data. , 2001, Journal of clinical epidemiology.
[168] T. Peters,et al. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. , 2001, Health technology assessment.
[169] H Goldstein,et al. A multilevel model framework for meta-analysis of clinical trials with binary outcomes. , 2000, Statistics in medicine.
[170] E. Antman,et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. , 2000, JAMA.
[171] I Olkin,et al. Heterogeneity and statistical significance in meta-analysis: an empirical study of 125 meta-analyses. , 2000, Statistics in medicine.
[172] C D Naylor,et al. Subgroups, treatment effects, and baseline risks: some lessons from major cardiovascular trials. , 2000, American heart journal.
[173] S. Assmann,et al. Subgroup analysis and other (mis)uses of baseline data in clinical trials , 2000, The Lancet.
[174] D A Follmann,et al. A Multivariate Test of Interaction for Use in Clinical Trials , 1999, Biometrics.
[175] P. Rothwell,et al. Prediction of benefit from carotid endarterectomy in individual patients: a risk-modelling study. European Carotid Surgery Trialists' Collaborative Group. , 1999, Lancet.
[176] J P Ornato,et al. Use of the Acute Cardiac Ischemia Time-Insensitive Predictive Instrument (ACI-TIPI) To Assist with Triage of Patients with Chest Pain or Other Symptoms Suggestive of Acute Cardiac Ischemia: A Multicenter, Controlled Clinical Trial , 1998, Annals of Internal Medicine.
[177] J. Ioannidis,et al. Heterogeneity of the baseline risk within patient populations of clinical trials: a proposed evaluation algorithm. , 1998, American journal of epidemiology.
[178] D. Roden. Mechanisms and management of proarrhythmia. , 1998, The American journal of cardiology.
[179] J. Lau,et al. The impact of high-risk patients on the results of clinical trials. , 1997, Journal of clinical epidemiology.
[180] A. Ahlbom,et al. How to evaluate interaction between causes: a review of practices in cardiovascular epidemiology , 1996, Journal of internal medicine.
[181] I. Tannock,et al. False-positive results in clinical trials: multiple significance tests and the problem of unreported comparisons. , 1996, Journal of the National Cancer Institute.
[182] C R Weinberg,et al. How bad is categorization? , 1995, Epidemiology.
[183] S Greenland,et al. Avoiding power loss associated with categorization and ordinal scores in dose-response and trend analysis. , 1995, Epidemiology.
[184] P. Rothwell,et al. Can overall results of clinical trials be applied to all patients? , 1995, The Lancet.
[185] A. Chant,et al. Can overall results of clinical trials be applied to all patients? , 1995, Lancet.
[186] G H Guyatt,et al. A Consumer's Guide to Subgroup Analyses , 1992, Annals of Internal Medicine.
[187] S. Zeger,et al. On estimating efficacy from clinical trials. , 1991, Statistics in medicine.
[188] R A Stallones,et al. The use and abuse of subgroup analysis in epidemiological research. , 1987, Preventive medicine.
[189] D P Byar,et al. Assessing apparent treatment--covariate interactions in randomized clinical trials. , 1985, Statistics in medicine.
[190] C. Furberg,et al. What do subgroup analyses reveal about differential response to beta-blocker therapy? The Beta-Blocker Heart Attack Trial experience. , 1983, Circulation.
[191] S Greenland,et al. Concepts of interaction. , 1980, American journal of epidemiology.
[192] D. Byar. Why data bases should not replace randomized clinical trials. , 1980, Biometrics.
[193] J. Kassirer,et al. The threshold approach to clinical decision making. , 1980, The New England journal of medicine.